{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-042266","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2024-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.160343+00:00","generated_at":"2026-05-30T20:21:12.195442+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bioventus divests Advanced Rehabilitation business to Accelmed for up to $45M","bullets":["Total cash consideration of $45M: $25M at close plus up to $20M in earn-outs.","Net proceeds of ~$20M after fees and expenses will be used to repay existing debt.","Divestiture reduces annual revenue by ~$50M and annual Adj. EBITDA by ~$6M.","Transaction expected to close in Q4 2024, subject to customary conditions.","Bioventus to focus on core business and improve liquidity with the sale."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-042266","json":"https://secwatch.observer/filing/0001628280-24-042266.json","markdown":"https://secwatch.observer/filing/0001628280-24-042266.md","text":"https://secwatch.observer/filing/0001628280-24-042266.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024042266/0001628280-24-042266-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024042266/bvs-20240930.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T20:21:12.195442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}